Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Mycobacterium tuberculosis releases an antacid that remodels phagosomes.

Buter J, Cheng TY, Ghanem M, Grootemaat AE, Raman S, Feng X, Plantijn AR, Ennis T, Wang J, Cotton RN, Layre E, Ramnarine AK, Mayfield JA, Young DC, Jezek Martinot A, Siddiqi N, Wakabayashi S, Botella H, Calderon R, Murray M, Ehrt S, Snider BB, Reed MB, Oldfield E, Tan S, Rubin EJ, Behr MA, van der Wel NN, Minnaard AJ, Moody DB.

Nat Chem Biol. 2019 Sep;15(9):889-899. doi: 10.1038/s41589-019-0336-0. Epub 2019 Aug 19.

PMID:
31427817
2.

Total Synthesis of an Immunogenic Trehalose Phospholipid from Salmonella Typhi and Elucidation of Its sn-Regiochemistry by Mass Spectrometry.

Mishra VK, Buter J, Blevins MS, Witte MD, Van Rhijn I, Moody DB, Brodbelt JS, Minnaard AJ.

Org Lett. 2019 Jul 5;21(13):5126-5131. doi: 10.1021/acs.orglett.9b01725. Epub 2019 Jun 20.

3.

Discovery of Salmonella trehalose phospholipids reveals functional convergence with mycobacteria.

Reinink P, Buter J, Mishra VK, Ishikawa E, Cheng TY, Willemsen PTJ, Porwollik S, Brennan PJ, Heinz E, Mayfield JA, Dougan G, van Els CA, Cerundolo V, Napolitani G, Yamasaki S, Minnaard AJ, McClelland M, Moody DB, Van Rhijn I.

J Exp Med. 2019 Apr 1;216(4):757-771. doi: 10.1084/jem.20181812. Epub 2019 Feb 25.

4.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group.

Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.

5.

The course of sexual interest and enjoyment in head and neck cancer patients treated with primary (chemo)radiotherapy.

Melissant HC, Jansen F, Schutte LER, Lissenberg-Witte BI, Buter J, Leemans CR, Sprangers MA, Vergeer MR, Laan ETM, Verdonck-de Leeuw IM.

Oral Oncol. 2018 Aug;83:120-126. doi: 10.1016/j.oraloncology.2018.06.016. Epub 2018 Jun 22.

6.

Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.

Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, Tesselaar MET, Jonker MA, Flucke UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group, van der Graaf WTA, van Herpen CML.

Head Neck. 2018 Mar;40(3):605-613. doi: 10.1002/hed.25035. Epub 2017 Dec 22.

7.

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.

Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300.

8.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

9.

Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program.

Cnossen IC, van Uden-Kraan CF, Witte BI, Aalders YJ, de Goede CJ, de Bree R, Doornaert P, Rietveld DH, Buter J, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM.

Eur Arch Otorhinolaryngol. 2017 Feb;274(2):1129-1138. doi: 10.1007/s00405-016-4367-9. Epub 2016 Nov 3.

10.

Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck.

van Weert S, Reinhard R, Bloemena E, Buter J, Witte BI, Vergeer MR, Leemans CR.

Head Neck. 2017 Mar;39(3):456-463. doi: 10.1002/hed.24613. Epub 2016 Oct 24.

PMID:
27775851
11.

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.

Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM.

Head Neck. 2017 Jan;39(1):140-146. doi: 10.1002/hed.24556. Epub 2016 Aug 10.

12.

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.

van Linde ME, van der Mijn JC, Pham TV, Knol JC, Wedekind LE, Hovinga KE, Aliaga ES, Buter J, Jimenez CR, Reijneveld JC, Verheul HM.

J Neurooncol. 2016 Sep;129(2):221-30. doi: 10.1007/s11060-016-2178-x. Epub 2016 Jul 21.

13.

Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.

Holla FK, Postma TJ, Blankenstein MA, van Mierlo TJM, Vos MJ, Sizoo EM, de Groot M, Uitdehaag BMJ, Buter J, Klein M, Reijneveld JC, Heimans JJ.

J Neurooncol. 2016 Sep;129(3):525-532. doi: 10.1007/s11060-016-2204-z. Epub 2016 Jul 11.

14.

Stereoselective Synthesis of 1-Tuberculosinyl Adenosine; a Virulence Factor of Mycobacterium tuberculosis.

Buter J, Heijnen D, Wan IC, Bickelhaupt FM, Young DC, Otten E, Moody DB, Minnaard AJ.

J Org Chem. 2016 Aug 5;81(15):6686-96. doi: 10.1021/acs.joc.6b01332. Epub 2016 Jul 26.

15.

Palladium-Catalyzed, tert-Butyllithium-Mediated Dimerization of Aryl Halides and Its Application in the Atropselective Total Synthesis of Mastigophorene A.

Buter J, Heijnen D, Vila C, Hornillos V, Otten E, Giannerini M, Minnaard AJ, Feringa BL.

Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3620-4. doi: 10.1002/anie.201510328. Epub 2016 Feb 16.

PMID:
26878822
16.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

17.

Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review.

Putten L, Bree R, Doornaert PA, Buter J, Eerenstein SE, Rietveld DH, Kuik DJ, Leemans CR.

Acta Otorhinolaryngol Ital. 2015 Jun;35(3):162-72. Review.

18.

Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI.

Rinkel RN, Verdonck-de Leeuw IM, Doornaert P, Buter J, de Bree R, Langendijk JA, Aaronson NK, Leemans CR.

Eur Arch Otorhinolaryngol. 2016 Jul;273(7):1849-55. doi: 10.1007/s00405-015-3680-z. Epub 2015 Jun 14.

19.

In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection.

Young DC, Layre E, Pan SJ, Tapley A, Adamson J, Seshadri C, Wu Z, Buter J, Minnaard AJ, Coscolla M, Gagneux S, Copin R, Ernst JD, Bishai WR, Snider BB, Moody DB.

Chem Biol. 2015 Apr 23;22(4):516-526. doi: 10.1016/j.chembiol.2015.03.015.

20.

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.

van der Linden N, Buter J, Pescott CP, Lalisang RI, de Boer JP, de Graeff A, van Herpen CM, Baatenburg de Jong RJ, Uyl-de Groot CA.

Eur Arch Otorhinolaryngol. 2016 Feb;273(2):455-64. doi: 10.1007/s00405-015-3495-y. Epub 2015 Jan 21.

21.

Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer.

Heukelom J, Lopez-Yurda M, Balm AJ, Wijers OB, Buter J, Gregor T, Wiggenraad R, de Boer JP, Tan IB, Verheij M, Sonke JJ, Rasch CR.

Head Neck. 2016 Apr;38 Suppl 1:E488-93. doi: 10.1002/hed.24023. Epub 2015 Jul 6.

PMID:
25728984
22.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
24.

Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.

van der Linden N, van Gils CW, Pescott CP, Buter J, Vergeer MR, Groot CA.

Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2007-16. doi: 10.1007/s00405-014-3106-3. Epub 2014 Jun 19.

PMID:
24943191
25.

Asymmetric total synthesis of a putative sex pheromone component from the parasitoid wasp Trichogramma turkestanica.

Geerdink D, Buter J, van Beek TA, Minnaard AJ.

Beilstein J Org Chem. 2014 Apr 2;10:761-6. doi: 10.3762/bjoc.10.71. eCollection 2014.

26.

The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study.

Verdonck-de Leeuw IM, Buffart LM, Heymans MW, Rietveld DH, Doornaert P, de Bree R, Buter J, Aaronson NK, Slotman BJ, Leemans CR, Langendijk JA.

Radiother Oncol. 2014 Mar;110(3):422-8. doi: 10.1016/j.radonc.2014.01.002. Epub 2014 Feb 25.

PMID:
24582144
27.

Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378c.

Layre E, Lee HJ, Young DC, Martinot AJ, Buter J, Minnaard AJ, Annand JW, Fortune SM, Snider BB, Matsunaga I, Rubin EJ, Alber T, Moody DB.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):2978-83. doi: 10.1073/pnas.1315883111. Epub 2014 Feb 10.

28.

A protecting group-free synthesis of the Colorado potato beetle pheromone.

Wu Z, Jäger M, Buter J, Minnaard AJ.

Beilstein J Org Chem. 2013 Nov 6;9:2374-7. doi: 10.3762/bjoc.9.273. eCollection 2013.

29.

Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.

Froklage FE, Oosterbaan LJ, Sizoo EM, de Groot M, Bosma I, Sanchez E, Douw L, Heimans JJ, Reijneveld JC, Lagerwaard FJ, Buter J, Uitdehaag BM, Klein M, Postma TJ.

J Neurooncol. 2014 Jan;116(2):387-94. doi: 10.1007/s11060-013-1310-4. Epub 2013 Nov 22.

PMID:
24264531
30.

Recurrent dyspnea following a swollen leg in a 46-year-old man.

Post JP, Westgeest HM, Blankensteijn JD, van der Meijs B, Klaassen RJL, Nossent E, Grünberg K, Buter J, Serné EH.

Chest. 2013 Oct;144(4):1402-1405. doi: 10.1378/chest.13-0390. No abstract available.

PMID:
24081354
31.

Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results.

van der Linden N, van Gils CW, Pescott CP, Buter J, Uyl-de Groot CA.

Eur Arch Otorhinolaryngol. 2014 Jun;271(6):1673-8. doi: 10.1007/s00405-013-2646-2. Epub 2013 Aug 2.

PMID:
23907370
32.

IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam AG, Santegoets SJ, Tijssen HJ, Buter J, Pinedo HM, van den Eertwegh AJ, Scheper RJ, Koenen HJ, van de Ven R, de Gruijl TD.

PLoS One. 2013 Jul 18;8(7):e70237. doi: 10.1371/journal.pone.0070237. Print 2013.

33.

Synthesis and analysis of the all-(S) side chain of phosphomycoketides: a test of NMR predictions for saturated oligoisoprenoid stereoisomers.

Buter J, Yeh EA, Budavich OW, Damodaran K, Minnaard AJ, Curran DP.

J Org Chem. 2013 May 17;78(10):4913-8. doi: 10.1021/jo4005298. Epub 2013 Apr 25.

34.

Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice.

Cnossen IC, de Bree R, Rinkel RN, Eerenstein SE, Rietveld DH, Doornaert P, Buter J, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM.

Support Care Cancer. 2012 Nov;20(11):2925-31. doi: 10.1007/s00520-012-1422-y. Epub 2012 Mar 7.

35.

Subset of patients with verrucous carcinoma of the oral cavity who benefit from treatment with methotrexate.

Karagozoglu KH, Buter J, Leemans CR, Rietveld DH, van den Vijfeijken S, van der Waal I.

Br J Oral Maxillofac Surg. 2012 Sep;50(6):513-8. doi: 10.1016/j.bjoms.2011.09.011. Epub 2011 Oct 14.

PMID:
22000636
36.

MRI and thallium-201 SPECT in the prediction of survival in glioma.

Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske DP, Postma TJ.

Neuroradiology. 2012 Jun;54(6):539-46. doi: 10.1007/s00234-011-0908-5. Epub 2011 Jul 14.

PMID:
21755329
37.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS.

Br J Cancer. 2011 Jun 28;105(1):44-52. doi: 10.1038/bjc.2011.182. Epub 2011 May 31.

38.

Salvage laryngectomy: oncological and functional outcome.

van der Putten L, de Bree R, Kuik DJ, Rietveld DH, Buter J, Eerenstein SE, Leemans CR.

Oral Oncol. 2011 Apr;47(4):296-301. doi: 10.1016/j.oraloncology.2011.02.002. Epub 2011 Feb 26.

PMID:
21356604
39.

Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer.

Knegjens JL, Hauptmann M, Pameijer FA, Balm AJ, Hoebers FJ, de Bois JA, Kaanders JH, van Herpen CM, Verhoef CG, Wijers OB, Wiggenraad RG, Buter J, Rasch CR.

Head Neck. 2011 Mar;33(3):375-82. doi: 10.1002/hed.21459.

PMID:
20629076
40.

Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial.

Rasch CR, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, Wiggenraad R, de Boer JP, Ackerstaff AH, Kroger R, Hoebers FJ, Balm AJ, Hilgers FJ.

Cancer. 2010 May 1;116(9):2159-65. doi: 10.1002/cncr.24916. Erratum in: Cancer. 2010 Aug 1;116(15):3750. Hilgers, Frans J [added].

41.

[Course of disease and treatment policy in suspected low-grade glioma].

Sizoo EM, Reijneveld JC, Lagerwaard FJ, Buter J, Taphoorn MJ, Hamer PC.

Ned Tijdschr Geneeskd. 2010;154:A1367. Review. Dutch.

PMID:
20170560
42.

Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.

Hilverda K, Bosma I, Heimans JJ, Postma TJ, Peter Vandertop W, Slotman BJ, Buter J, Reijneveld JC, Klein M.

J Neurooncol. 2010 Mar;97(1):89-94. doi: 10.1007/s11060-009-9993-2. Epub 2009 Aug 30.

43.

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, Kelly C, de Raucourt D, Harrington KJ.

Ann Oncol. 2009 Jul;20(7):1275-9. doi: 10.1093/annonc/mdn775. Epub 2009 Feb 26.

PMID:
19246715
44.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorken JB.

Eur J Cancer. 2008 Nov;44(17):2542-5. doi: 10.1016/j.ejca.2008.08.014. Epub 2008 Sep 24.

PMID:
18819792
45.

[Medical treatment of solid tumours].

Buter J.

Ned Tijdschr Tandheelkd. 2008 Apr;115(4):201-2. Review. Dutch.

PMID:
18512518
46.

Subsequent tumors in retinoblastoma survivors: the role of the head and neck surgeon.

de Bree R, Moll AC, Imhof SM, Buter J, Leemans CR.

Oral Oncol. 2008 Oct;44(10):982-5. doi: 10.1016/j.oraloncology.2007.12.005. Epub 2008 Feb 15.

PMID:
18280773
47.

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G.

Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21.

PMID:
17185744
48.

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.

Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.

49.

A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance.

de Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den Eertwegh AJ, Scheper RJ, Pinedo HM.

J Immunol. 2006 Jun 15;176(12):7232-42.

50.

Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation.

Vergeer MR, Doornaert P, Leemans CR, Buter J, Slotman BJ, Langendijk JA.

Radiother Oncol. 2006 Apr;79(1):39-44.

PMID:
16632006

Supplemental Content

Support Center